Therapeutic potential of targeting AKR1C2 in the treatment of prostate cancer
Authors:
- 18 September 2024
- journal article
- review article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-7
Abstract
Prostate cancer development and progression are driven by androgens, and changes in androgen metabolic pathways can lead to prostate cancer progression or remission. AKR1C2 is a member of the aldo-keto reductase superfamily and plays an important role in the metabolism of steroids and prostaglandins. Alterations in the expression and activity of AKR1C2 affect the homeostasis of active androgens, which in turn affects the progression of prostate cancer. AKR1C2 reduces the highly active dihydrotestosterone to the less active 3α-diol in the prostate, resulting in lower androgen levels. Whereas the expression of AKR1C2 is significantly reduced in prostate cancer tissues relative to normal prostate tissues, this results in a weakening of the dihydrotestosterone metabolic inactivation pathway, leading to the retention of dihydrotestosterone in the prostate cancer cells, which promotes the progress of prostate cancer. Given the critical role of AKR1C2 in prostate cancer cells, targeting AKR1C2 for the treatment of prostate cancer may be an effective strategy. It has been demonstrated that curcumin and neem leaf extract effectively inhibit prostate cancer in vitro and in vivo by modulating AKR1C2.Keywords
Funding Information
- Foundation of Guangxi Key Laboratory of Marine Drugs (LMD2023-4)
This publication has 52 references indexed in Scilit:
- 3α-Hydroxysteroid Dehydrogenase Type III Deficiency: A Novel Mechanism for HirsutismThe Journal of Clinical Endocrinology & Metabolism, 2008
- 5α-Androstane-3β,17β-diol (3β-diol), an estrogenic metabolite of 5α-dihydrotestosterone, is a potent modulator of estrogen receptor ERβ expression in the ventral prostrate of adult ratsSteroids, 2007
- Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancerInternational Journal of Oncology, 2007
- Impaired Dihydrotestosterone Catabolism in Human Prostate Cancer: Critical Role of AKR1C2 as a Pre-Receptor Regulator of Androgen Receptor SignalingCancer Research, 2007
- Δ-4-Androstene-3,17-Dione Binds Androgen Receptor, Promotes Myogenesisin Vitro, and Increases Serum Testosterone Levels, Fat-Free Mass, and Muscle Strength in Hypogonadal MenThe Journal of Clinical Endocrinology & Metabolism, 2005
- Selective Loss of AKR1C1 and AKR1C2 in Breast Cancer and Their Potential Effect on Progesterone SignalingCancer Research, 2004
- Nilutamide as Second Line Hormone Therapy for Prostate Cancer After Androgen Ablation FailsJournal of Urology, 2003
- Role of human type 3 3α-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cancer cellsChemico-Biological Interactions, 2003
- Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolismThe Prostate, 2003
- Curcumin downregulates cell survival mechanisms in human prostate cancer cell linesOncogene, 2001